

Scientific Program

BIOCHEMISTRY/MOLECULAR ONCOLOGY

Room A, 09:00-11:00
Thursday, October 6

Chair Persons: N.E. Burgis, Y. Fan, A.C.O. Vertegaal

- 201. Site-directed mutagenesis of human ITPase: New tools to study heart development and metabolism of thiopurines and ribavirin. **N.E. Burgis** (Cheney, WA, USA) (30')
- 211. Role of H1 linker histones in cancer. **Y. Fan**, M. Magdalena, Y. Zhang, K. Cao (Atlanta, GA, USA) (30')
- 261. Proteomic approaches to dissect ubiquitin-like signaling pathways. I.A. Hendriks, J. Schimmel, I. Matic, M. Mann, **A.C.O. Vertegaal** (Leiden, The Netherlands; Martinsried, Germany) (30')
- 178. Small molecule inhibitors of the neuropilin-1 VEGF-A interaction. **S. Djordjevic**, C.K. Allerston, A. Jarvis, H. Jia, B. Herzog, A. Garza-Garcia, P.C. Driscoll, I. Zachary, D. Selwood (London; Cambridge, UK) (30')

SIGNAL TRANSDUCTION

Room A, 11:30-13:10
Thursday, October 6

Chair Persons: N. Latruffe, E. Marcinkowska

- 104. mi-RNA, as new signaling molecules of resveratrol-mediated anti-inflammatory and anti-cancer effects. **N. Latruffe**, E. Tili, D. Delmas, E. Limagne, J.-J. Michaille, C.M. Croce (Dijon, France; Columbus, OH, USA) (25')
- 144. Regulation of vitamin D-induced leukemic cell differentiation at levels of intracellular signal transduction, gene transcription and protein stability. H. Bauriska, E. Gocek, M. Kielbinski, A. Klotz, D. Gawron, A. Kutner, **E. Marcinkowska** (Wroclaw; Warszawa, Poland) (25')
- 156. Sensitization of cancer stem cells based on inhibiting key signal transduction pathways. **L.S. Steelman**, S. Abrams, W.H. Chappell, A.M. Martelli, F. Nicoletti, P. Fagone, C. Mazzarino, G. Malaponte, M. Libra, F. Stivala, M. Cervello, S. Mijatovic, D. Maksimovic-Ivanic, J.A. McCubrey (Greenville, NC, USA; Bologna; Catania; Palermo, Italy; Belgrade, Serbia) (25')
- 371. Novel AMPK/CRTC signaling pathway in metabolism and lung cancer. **F.J. Kaye** (Gainesville, FL, USA) (25')

GENETICS/CANCER THERAPEUTICS

Room A, 16:00-17:30
Thursday, October 6

Chair Persons: M. Lipoldová, H. Modjtahedi

- 132. Genetic link between genes that control lymphocyte activation and susceptibility to cancer. **M. Lipoldová**, H. Havelková, J. Badalová, J. Vojtíšková, L. Quan, M. Krulová, Y. Sohrabi, A.P. Stassen, P. Demant (Prague, Czech Republic; Buffalo, NY, USA; Maastricht, The Netherlands) (30')
- 204. EGFR and HER-2 co-targeting in cancer. **H. Modjtahedi**, S.A. Khelwatty, S. Essapen, A.M. Seddon (Kingston; Guildford, UK) (30')
- 300. Computational methods in epitope discovery. **C. Lundegaard** (Lyngby, Denmark) (30')

SIGNALING/IMMUNOLOGY

Room A, 18:00-19:30
Thursday, October 6

Chair Persons: T. Grundström, N. Rivard, M.-J. Boucher

- 265. Regulatory mechanisms controlling diversification and affinity maturation of antibodies. J. Hauser, J. Verma-Gaur, A. Wallenius, **T. Grundström** (Umeå, Sweden) (30')
- 149. Regulation of ERK signalling by DUSP4 in intestinal cancer cells. **N. Rivard**, S. Cagnol (Sherbrooke, Canada) (30')
- 225. Regulation of Notch signalling by the Mek/Erk pathway. I. Tremblay, **M.-J. Boucher** (Sherbrooke, Canada) (30')

EXPERIMENTAL ONCOLOGY/PHARMACOLOGY

Room B, 09:00-11:00
Thursday, October 6

Chair Persons: Y. Suzuki, G. Fritz

165. H₂O₂ acts as a tumor-selective cytotoxic agent toward human melanoma cells: Roles of mitochondrial superoxide generation and endoplasmic reticulum stress. **Y. Suzuki**, T. Inoue, M. Tochigi, M. Murai, M. Suzuki-Karasaki, T. Ochiai, C. Ra (Tokyo, Japan) (30')
169. Clinical proteomics: A novel tool for molecular diagnostics in oncology. **A. Alaiya**, Z. Shinwari, C. Adra (Riyadh, Saudi Arabia; Boston, MA, USA) (30')
177. Beneficial effects of statins on anticancer drug-induced normal tissue damage. C. Henninger, J. Huelsenbeck, S. Huelsenbeck, M. Herzog, B. Kaina, **G. Fritz** (Mainz; Düsseldorf, Germany) (30')
106. Targeting of transcription factor DNA binding activities using heterocyclic diamidines as sequence-specific DNA ligands. R. Nhili, P. Peixoto, S. Depauw, **M.-H. David-Cordonnier** (Lille, France) (15')
160. Gene expression differences in primary fibroblasts between patients with one and two neoplasms in childhood. **M. Marron**, A. Victora, E. Weis, C.M. Messow, B. Schneider-Rätzke, N. Kohlschmitt, T. Haaf, C. Spix, D. Galetzka (Mainz; Würzburg, Germany) (15')

CLINICAL ONCOLOGY/MOLECULAR ONCOLOGY

Room B, 11:30-13:00
Thursday, October 6

Chair Persons: T. Mainou-Fowler, A. Vral

130. MicroRNAs in B-cell chronic lymphocytic leukaemia (B-CLL): Mature microRNAs of the miR-17-92 cluster predict for treatment free survival (TFS) in patients with B-CLL. R. Culpin, K. Pearce, J. Bailey, J. Pointon, N. Sunter, J. Bailey, P. Evans, D. Allsup, J. Allan, **T. Mainou-Fowler** (Newcastle upon Tyne; Hull; Leeds, UK) (30')
131. Mature microRNAs of the miR-17-92 cluster predict for disease outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with CHOP-R immunochemotherapy. **R. Culpin**, M. Sieniawski, J. Anderson, B. Angus, S. Proctor, G. Menon, K. McCabe, P. Milne, S. Crosier, T. Mainou-Fowler (Newcastle upon Tyne, UK) (15')
121. The clinical significance of RhoGDI2 expression in advanced gastric cancer. **W.S. Lee**, S.-H. Cho, D.C. Kim, M.H. Kang, M.J. Lee, M.J. Kim, S.-I. Go, H.-G. Kim, J.-H. Lee, G.H. Ko, S.C. Hong, W.S. Ha (Jinju, Republic of Korea) (15')
151. WT1 expression as prognostic factor correlates with cell proliferation and angiogenesis in endometrial cancer. **S. Dohi**, S. Ohno, Y. Ohno, S. Kyo, G.-I. Soma, H. Sugiyama, M. Inoue (Ishikawa; Tokyo; Tokushima; Chiba; Osaka, Japan) (15')
216. The efficiency of mammography X-rays in inducing DNA double-strand breaks and chromosomal damage. J. Depuydt, A. Baert, V. Vandersickel, H. Thierens, **A. Vral** (Ghent, Belgium) (15')

MOLECULAR BIOLOGY/BREAST CANCER

Room B, 16:00-17:30
Thursday, October 6

Chair Persons: A. Ben-Baruch, R. Gambari

168. Breast cancer: Inflammatory mediators of the tumor milieu and their tumor-host interactions. G. Soria, K. Haim, M. Ofri-Shahak, T. Leibovich-Rivkin, T. Meshel, P. Weizenfeld, I. Haas, N. Yaal-Hahoshen, L. Leider-Trejo, E. Shabtai, **A. Ben-Baruch** (Tel Aviv, Israel) (30')
315. Peptide nucleic acids and surface plasmon resonance technology for detection of point mutations of genetic diseases. **R. Gambari** (Ferrara, Italy) (30')
267. Progesterone metabolism in endometriosis: Do 5 α -pregnanes stimulate proliferation of endometriotic cells? **T. Lanišnik Rižner**, N. Beranič, N. Hevir, A. Starzinski-Powitz (Ljubljana, Slovenia; Frankfurt, Germany) (30')

APOPTOSIS/MOLECULAR ONCOLOGY

Room B, 18:00-19:30
Thursday, October 6

Chair Persons: R. Kiss, G. Schneider

107. The sodium pump (the Na⁺/K⁺-ATPase) alpha-1 and alpha-3 subunits as novel targets to combat apoptosis- and/or multidrug-resistant proliferating and migrating cancer cells. **R. Kiss** (Brussels, Belgium) (30')
105. Apoptotic pathways in pancreatic cancer. **G. Schneider** (München, Germany) (30')
113. Role of NF- κ B, the 26S proteasome and Nrf2 in chemoresistance of pancreatic cancer. **A. Arlt**, S. Sebens, H. Schäfer (Kiel, Germany) (30')

BRAIN TUMORS

Room C, 09:00-11:00
Thursday, October 6

Chair Persons: F. Lefranc, P. Hülper, C. Hagemann

108. Narciclasine, an old compound with novel mechanisms of action, is a promising weapon against brain tumors. **F. Lefranc** (Brussels, Belgium) (30')
194. Effect of anti-TGF- β antibody on experimental glioblastomas. **P. Hülper**, W. Schulz-Schaeffer, C. Dullin, P. Hoffmann, J. Harper, L. Kurtzberg, S. Lonning, W. Kugler, B. Erdlenbruch, M. Lakomek (Göttingen; Minden, Germany; Cambridge, MA; Framingham, MA, USA) (30')
221. Macrophage-mediated host defense in the C6 experimental glioma implantation model. **C. Hagemann**, C. Várallyay, J. Heinrich, T. Linsenmann, R.-I. Ernestus, G.H. Vince (Würzburg, Germany) (30')
237. Extracellular matrix molecules in normal brain and invasive glioma. **M. Wiranowska** (Tampa, FL, USA) (30')

MOLECULAR ONCOLOGY

Room C, 11:30-13:10
Thursday, October 6

Chair Persons: S. Heinsohn, J. Brieger

257. Activation-induced cytidine deaminase (AID) expression in childhood lymphoma and association with SV40 infection and p53 mutation. **S. Heinsohn**, H. Kabisch (Hamburg, Germany) (25')
129. Enhanced proliferation of squamous cell carcinoma after combined irradiation/anti-vascular endothelial growth factor treatment. **J. Brieger**, K. Fruth, Y. Oxcu, W.J. Mann (Mainz, Germany) (15')
103. From generic gastro-enteric diseases to cancer: A family case study by molecular approaches. A. De Maio, S. Imperato, C. Formisano, G. Galloro, C. Ferreri, **M.R. Faraone-Mennella** (Naples; Bologna, Italy) (15')
128. High functionality of Lynch syndrome-related DNA mismatch repair heterodimer MutLalpha - Is there a power button? **A. Brieger**, S. Passmann, S. Zeuzem (Frankfurt, Germany) (15')
239. Tumor suppressive microRNA-1/-133a regulates multiple oncogenes in maxillary sinus squamous cell carcinoma. **N. Nohata**, T. Hanazawa, T. Kinoshita, N. Kikkawa, M. Mutallip, T. Chiyomaru, K. Kawakami, H. Yoshino, H. Enokida, M. Nakagawa, Y. Okamoto, N. Seki (Chiba; Kagoshima, Japan) (15')
382. NF- κ B long-time regulation and mitochondrial localization after cytokine treatment in a human hepatoma cell line. **P. Kohlhof**, D. Techel (Stuttgart; Heidelberg, Germany) (15')

IMMUNOLOGY/MOLECULAR ONCOLOGY

Room C, 16:00-17:30
Thursday, October 6

Chair Persons: L. Vannucci, M.H. Kershaw

229. Innate immunity, cancer and microenvironments: A perspective view by a renewed morpho-functional approach. **L. Vannucci**, O. Chernyavskiy, J. Krizan, R. Stepankova, M. Burocziova, V. Grobarova, L. Kubinova, J. Klepetar, J. Janacek, P. Rossmann, A. Fiserova, P. Vodicka, L. Lipska (Prague, Czech Republic) (30')
240. Differential responses to immunotherapy of orthotopic tumours compared to subcutaneous tumours. C. Devaud, J.A. Westwood, C. Duong, P.K. Darcy, **M.H. Kershaw** (Melbourne, Australia) (15')
234. The distribution of SATB1 in cells from patients with primary cutaneous T cell lymphoma (CTCL). **D. Grzanka**, A.A. Grzanka, M. Gagat, A. Marszalek, W. Placek (Bydgoszcz; Poznan, Poland) (15')
241. Immunomodulatory effects of all-trans-retinoic acid (ATRA) and IL-12 on cyclophosphamide and tumour-induced myeloid-derived suppressor cells. **M. Indrová**, R. Mikyšková, J. Bieblová, M. Reiniš (Prague, Czech Republic) (15')
355. A role for angiotensin converting enzyme inhibition in lung cancer chemoprevention. **W.J. Petty**, V.A. Varela, C.B. Swift, J.J. Urbanic (Winston-Salem, NC, USA) (15')

MOLECULAR ONCOLOGY/PHARMACOLOGY

Room C, 18:00-19:30
Thursday, October 6

Chair Persons: B. Köberle, N. Ohtomo

175. DNA damage response in cisplatin sensitive testis tumor cells. S. Usanova, A. Piée-Staffa, U. Heinicke, P. Clauß, B. Kaina, **B. Köberle** (Mainz, Germany) (25')
213. Expression of alpha-taxilin correlates with growth activity and malignant potential of hepatocellular carcinoma. **N. Ohtomo**, H. Shirataki, T. Tomiya (Tokyo; Tochigi, Japan) (20')
246. The prognostic impact of Akt isoforms, PI3K and PTEN in soft tissue sarcomas. **A. Valkov**, S.W. Sorbye, T.K. Kilvaer, T. Donnem, E. Smeland, R.M. Bremnes, L.-T. Busund (Tromsø, Norway) (15')
277. Effects of zebularine in childhood acute lymphoblastic leukemia cell lines. **V.S. Silveira**, A.F. Andrade, K.S. Borges, A.M.C. Gamero, D.A. Moreno, R.G.P. Queiroz, C.A. Scrideli, L.G. Tone (Sao Paulo, Brazil) (15')
278. A novel treatment strategy targeting Aurora kinases in childhood adrenocortical tumor. **K.S. Borges**, D.A. Moreno, C.E. Martinelli, S.R.R. Antonini, M. Castro, S. Tucci Jr, L. Neder, A.L. Seidinger, M.J. Mastellaro, J.A. Yunes, S.R. Brandalise, L.G. Tone, C.A. Scrideli (São Paulo; Campinas, Brazil) (15')

MOLECULAR MEDICINE

Room D, 09:00-11:00
Thursday, October 6

Chair Persons: C. Sato, T. Takahashi, A.V. Kuznetsov

- 356. Direct ASEM immuno-electron microscopy of cells in solution. T. Ebihara, T. Murai, Y. Maruyama, K. Mio, S. Manaka, H. Nishiyama, M. Suga, **C. Sato** (Tsukuba; Suita; Akishima, Japan) (20')
- 357. 3D structure of intramembrane-cleaving proteases and oxidative stress sensors using electron microscopy. K. Mio, T. Ogura, Y. Maruyama, T. Moriya, M. Kawata, **C. Sato** (Tsukuba, Japan) (20')
- 154. Is exhaled carbon monoxide concentration a marker of oxidative stress? **T. Takahashi** (Okayama, Japan) (25')
- 166. Multiple effects of doxorubicin on mitochondria. **A.V. Kuznetsov**, R. Margreiter, A. Amberger, V. Saks, M. Grimm (Innsbruck, Austria; Grenoble, France) (20')
- 167. The role of various isotypes of beta-tubulin in cardiomyocytes and cancerous HL-1 cells. **A.V. Kuznetsov**, M.G. Granillo, R. Guzun, R. Margreiter, M. Grimm, V. Saks (Innsbruck, Austria; Grenoble, France) (20')
- 147. Nrf2 activates the pentose phosphate pathway and glutamine consumption in proliferating cells. Y. Mitsuishi, K. Taguchi, M. Yamamoto, **H. Motohashi** (Sendai, Japan) (15')

MOLECULAR MEDICINE

Room D, 11:30-13:15
Thursday, October 6

Chair Persons: Y. Yamada, M. Hiramatsu

- 101. Association of genetic variants with myocardial infarction and intermediate phenotypes in East Asian populations. **Y. Yamada**, M. Hiramatsu (Tsu; Nagoya, Japan) (25')
- 102. Association of a polymorphism of *BTN2A1* with type 2 diabetes mellitus, hypertension, and chronic kidney disease in Japanese individuals. **M. Hiramatsu**, Y. Yamada (Nagoya; Tsu, Japan) (25')
- 358. 3D reconstruction of ion channels using a transmission electron microscopy. **K. Mio**, T. Ogura, Y. Maruyama, T. Moriya, M. Kawata, M. Mio, C. Sato (Tokyo, Japan) (25')
- 379. Effects of neuromuscular electrical stimulation training on skeletal muscle strength in elderly people. **T. Pietrangelo**, C. Doria, R. Mancinelli, G. Di Tano, G. Fano', S. Fulle (Chieti, Italy) (15')
- 381. Keap1 degradation by autophagy for the maintenance of redox homeostasis. N. Fujikawa, **K. Taguchi**, H. Motohashi, M. Yamamoto (Sendai, Japan) (15')

MOLECULAR MEDICINE

Room D, 16:00-17:30
Thursday, October 6

Chair Persons: K. Igarashi, Y. Ji

188. Strong correlation between brain infarction and acrolein produced from polyamines. **K. Igarashi**, R. Saiki, M. Yoshida, H. Tomitori, K. Kashiwagi (Chiba, Japan) (30')
189. Isolation and their characteristics of acrolein toxicity decreasing mutants from mouse mammary carcinoma and neuroblastoma cells. **H. Tomitori**, M. Nakamura, A. Sakamoto, Y. Terui, M. Yoshida, K. Kashiwagi, K. Igarashi (Chiba, Japan) (15')
212. Targeting of the RAG proteins during the initiation of V(D)J recombination. **Y. Ji** (Xian, P.R. China) (30')
287. Insulin resistance and dyslipidemia are increased in patients with multiple sclerosis. S.R. Oliveira, A.P. Kallaur, A.N.C. Simão, M.A.B. Lozovoy, D.R. Kaimen-Maciel, J. Lopes, H.K. Morimoto, **E.M.V. Reiche** (Londrina, Brazil) (15')

MOLECULAR MEDICINE/MOLECULAR ONCOLOGY

Room D, 18:00-19:30
Thursday, October 6

Chair Persons: I. Di Liegro, P.E. Nielsen, E.M.V. Reiche

205. Histone H1^o RNA-binding proteins in developing rat brain. C.M. Di Liegro, P. Saladino, G. Schiera, P. Proia, **I. Di Liegro** (Palermo, Italy) (30')
217. A future for genetic antibiotics? Antibacterial properties of antisense peptide nucleic acid (PNA) peptide conjugates. **P.E. Nielsen**, A. Ghosal (Copenhagen, Denmark) (30')
288. Tumor necrosis factor beta *Nco1* genetic polymorphism is associated with systemic lupus erythematosus in Brazilian patients. A.P. Kallaur, S.R. Oliveira, A.N.C. Simão, M.A.B. Lozovoy, H.K. Morimoto, E.R.D. De Almeida, T. Flauzino, I. Dichi, **E.M.V. Reiche** (Londrina, Brazil) (15')
349. Multipotency of Schwann cell precursors in embryonic peripheral nervous system opens new vistas for melanoma and neuroblastoma cancer research. **I. Adameyko**, F. Lallemand, A. Furlan, N. Zinin, S. Aranda, U. Suter, S. Nicolis, R. Favaro, P. Ernfors (Stockholm, Sweden; Zürich, Switzerland; Milano, Italy) (15')

EXPERIMENTAL THERAPEUTICS

Room A, 09:00-11:00
Friday, October 7

Chair Persons: A.M. Martelli, J.A. McCubrey, G.I. Botchkina

139. PI3K/Akt/mTOR signaling in T-cell acute lymphoblastic leukemia (T-ALL): A new option for targeted therapy. **A.M. Martelli**, C. Evangelisti, D. Bertagnin, J.A. McCubrey, F. Chiarini (Bologna, Italy; Greenville, NC, USA) (30')
155. Novel approaches to target the prostate cancer stem cell - Eliminating the root of the cancer. **J.A. McCubrey**, W.H. Chappell, S. Abrams, A.M. Martelli, F. Stivala, F. Nicoletti, P. Fagone, C. Mazzarino, G. Malaponte, M. Libra, M. Cervello, D. Maksimovic-Ivanic, S. Mijatovic, L.S. Steelman (Greenville, NC, USA; Bologna; Catania; Palermo, Italy; Belgrade, Serbia) (30')
172. Prostate and colon cancer stem cells as a novel target for anti-cancer drug development. **G.I. Botchkina** (Stony Brook, NY, USA) (30')
364. Catalytic DNA as new drugs for vascular disease and cancer. **L.M. Khachigian** (Sydney, Australia) (30')

EXPERIMENTAL THERAPEUTICS

Room A, 11:30-13:10
Friday, October 7

Chair Persons: A. Androutsellis-Theotokis, P.K. Darcy, R. Ketteler

161. A new brain tumor target: The STAT3/Hes3 pathway operating in cancer stem cells. **A. Androutsellis-Theotokis** (Dresden, Germany; Rome, Italy) (25')
202. Tumor ablation by gene-engineered T cells in the absence of autoimmunity. **P.K. Darcy**, L.X.J. Wang, J.A. Westwood, M. Moeller, C.P.M. Duong, W.-Z. Wei, J. Malaterre, J.A. Trapani, P. Neeson, M.J. Smyth, M.H. Kershaw (East Melbourne, Australia; Detroit, MI, USA) (25')
206. Accelerated tumor growth and enhanced tumor burden in genetically engineered animal models with targeted thymidylate synthase activation. **M. Zajac-Kaye** (Gainesville, FL, USA) (25')
370. Autophagy protease ATG4B as a target in drug discovery. J. Freeman, J. Kriston-Vizi, I. Lindenschmidt, M. Haider, **R. Ketteler** (London, UK) (25')

EXPERIMENTAL THERAPEUTICS

Room A, 15:00-16:30
Friday, October 7

Chair Persons: D.W. Felsher, M. Jhanwar-Uniyal, A.Y. Nikitin

208. Reversing oncogene-induced tumorigenesis. **D.W. Felsher** (Stanford, CA, USA) (30')
180. Novel targets of mTORC1/2 kinase in glioblastoma multiforme. **M. Jhanwar-Uniyal** (Valhalla, NY, USA) (30')
224. Targeting cancer propagating cells. S.J. Palmaccio, L. Cheng, A.V. Ramesh, A. Flesken-Nikitin, **A.Y. Nikitin** (Ithaca, NY, USA) (30')

MOLECULAR ONCOLOGY/TUMOR BIOLOGY

Room A, 17:00-18:30
Friday, October 7

Chair Persons: I. Maillard, L.M. Khachigian, T. McDonnell

314. A critical role for Notch signaling after allogeneic bone marrow transplantation. **I. Maillard**, A.R. Sandy, I.T. Tran, V. Radojcic, G.T. Shan, A. Friedman, P. King, Y. Zhang (Ann Arbor, MI, USA) (30')
365. Regulation of cell migration by activation transcription factor-4. **L.M. Khachigian**, A. Nath, K.P. Malabanan (Sydney, Australia) (30')
307. An expression signature of p53 functional status in multiple types of human cancer. **T. McDonnell**, N. Pinaire, K. Spurgers, N. Chari (Houston, TX, USA) (30')

APOPTOSIS/THERAPEUTICS

Room B, 09:00-11:00
Friday, October 7

Chair Persons: E. Krepela, W. Cao, S. Pandey

137. Inhibition of apoptosome apparatus in non-small cell lung cancer. **E. Krepela**, E. Moravcikova (Prague, Czech Republic) (30')
173. Selective induction of apoptosis in cancer cells by pancratistatin that targets mitochondria. **S. Pandey**, D. Ma, C. Griffin, C. Hamm, J. McNulty (Windsor; Hamilton, Canada) (30')
162. Apoptotic effects of sonodynamic therapy with protoporphyrin IX on SAS human tongue carcinoma cell and xenografts. **W. Cao**, J. Zheng, Y. Lv, W. Song, H. Cui, Z. Gao, H. Li (Harbin, P.R. China) (20')
163. Sonodynamic therapy with 5-aminolevulinic acid induce apoptosis in SAS cells via the mitochondrial mediated caspase pathway. J. Zheng, Y. Lv, H. Cui, H. Li, Z. Gao, **W. Cao** (Harbin, P.R. China) (20')
275. Lung cancer metabolic signatures unveiled by metabonomics. C.M. Rocha, J. Carrola, A.S. Barros, A.M. Gil, B.J. Goodfellow, I.M. Carreira, J. Bernardo, A. Gomes, V. Sousa, L. Carvalho, **I.F. Duarte** (Aveiro; Coimbra, Portugal) (20')

CANCER THERAPEUTICS/SIGNALING

Room B, 11:30-13:15
Friday, October 7

Chair Persons: W. Walther, J. Mahajna

293. Gene therapy strategies for tumor sensitization. **W. Walther**, D. Kobelt, J. Aumann, U. Stein, P.M. Schlag (Berlin, Germany) (30')
136. Abl kinase allosteric inhibitors as CML therapeutics. **J. Mahajna** (Kiryat Shmona, Israel) (15')
109. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. **R. Bhat**, S. Dempe, C. Dinsart, J. Rommelaere (Heidelberg, Germany) (15')
111. Engineered stem cells expressing suicide enzymes and interferon-beta migrated human invasive tumors and resulted in their growth inhibition in the presence of prodrugs. **K.-C. Choi** (Chungbuk, Republic of Korea) (15')
112. Synergistic therapeutic effect in cancer cells produced by oncolytic adenovirus encoding *Drosophila melanogaster* deoxyribonucleoside kinase. **X. Zheng**, Z. Zhu, L. Mao, L. Zhao, Z. Sun, H. Xu (Shenyang, P.R. China) (15')
283. Simvastatin induces early apoptosis and decreases cell viability in osteosarcoma and trophoblast cells, causing cell type-selective effects. **M.C. Sandoval-Usme**, N. Ordoñez-Herrera, A. Umaña-Perez, J.M. García-Castellano, L. Fernandez-Perez, M. Sanchez-Gomez (Bogotá, Colombia; Gran Canaria, Spain) (15')

APOPTOSIS/MOLECULAR ONCOLOGY

Room B, 15:00-16:30
Friday, October 7

Chair Persons: S. Emanuele, P. Juin

192. The mechanism of parthenolide-induced cell death in tumor cell lines. **S. Emanuele**, D. Carlisi, A. D'Anneo, M. Lauricella, R. Martinez, R. Vento, G. Tesoriere (Palermo, Italy) (30')
220. Molecular basis of cancer cell dependence on Bcl-2 family members. **P. Juin** (Nantes, France) (30')
222. Resveratrol induces apoptosis in Hodgkin lymphoma cells and inhibits SIRT1, a deacetylase expressed by germinal center-derived lymphocytes. **R. Frazzi**, I. Tamagnini, R. Valli, B. Casali, N. Latruffe, F. Merli (Reggio Emilia, Italy; Dijon, France) (15')
354. Characterizing canine lymphoma as a potential large animal model of human diffuse large B-cell lymphoma. **K.L. Richards**, A. Motsinger-Reif, D.M. Nielsen, R. Thomas, C. Smith, S.S. Dave, M. Breen, S.E. Suter (Chapel Hill, NC; Raleigh, NC; Durham, NC, USA) (15')

MOLECULAR ONCOLOGY/APOPTOSIS

Room B, 17:00-18:30
Friday, October 7

Chair Persons: C. Demonacos, W.K. Rathmell

359. The role of cytochromes P450 in cancer and their potential as targets for anti-cancer drug development. T. Leung, H. Alavi, K. Andreou, M. Krstic-Demonacos, **C. Demonacos** (Manchester, UK) (30')
330. Defining molecular subtypes of clear cell renal cell carcinoma. **W.K. Rathmell** (Chapel Hill, NC, USA) (30')
126. Induction of apoptosis in adult T-cell leukemia cells by a novel PDK-1 inhibitor DTCM-glutarimide. **A. Ito**, A. Kaneda, M. Takeiri, K. Umezawa (Yokohama, Japan) (15')
331. The transcription factor NFkappaB as a potential target to cell death induction in glioblastomas. **A. Zanotto-Filho**, E. Braganhol, A.M.O. Battastini, J.C.F. Moreira (Porto Alegre, Brazil) (15')

POSTERS WINE TASTING

POSTER VIEWING 18:30-19:30
Friday, October 7

BREAST CANCER

Room C, 09:00-11:00
Friday, October 7

Chair Persons: F. Recchia, R.J. Rosengren, D. Marchetti

- 308. Molecular signatures of circulating tumor cells from brain metastatic breast cancer patients. L. Zhang, M. Wetzel, L. Ridgway, T. Zaidi, W. He, R. Katz, W. Schoeber, M. Groves, **D. Marchetti** (Houston, TX, USA) (30')
- 143. Estradiol (E2) suppression in premenopausal (PM) breast cancer (BC): Its relation with vascular endothelial growth factor (VEGF) and T-regulatory cells (T-reg). **F. Recchia**, C.O.C. Recchia, S. Rea (Avezzano; L'Aquila, Italy) (30')
- 174. Low dose raloxifene causes tumor regression in a xenograft model of triple negative breast cancer. S. Taurin, K.M. Allen, J. Dzyk, **R.J. Rosengren** (Dunedin, New Zealand) (30')
- 138. Surface chondroitin sulfates as potential targets for anti-metastatic therapies in breast cancer. **B. Monzavi-Karbassi**, F. Jousheghany, A.M. Kieber-Emmons, A. Yao-Borengasser, T. Leakey, C.A. Cooney, E.R. Siegel (Little Rock, AR, USA) (30')

BREAST CANCER

Room C, 11:30-13:00
Friday, October 7

Chair Persons: M. Götte, R. Clarke

- 199. Overexpression of the Sulfotransferase HS3ST2 leads to increased MMP-activity and increased motility and invasiveness of MDA-MB-231 breast cancer cells. E.S. Gassar, S.A. Ibrahim, A.V. Kumar, D. Spillmann, C. Stock, L. Kiesel, G.W. Yip, **M. Götte** (Münster, Germany; Uppsala, Sweden; Singapore) (30')
- 210. Changes in cellular metabolism associated with acquired resistance to endocrine therapies in breast cancer. A.N. Shahajan, C.O.B. Facey, K. Cook, A. Cheema, E. Hickman, H. Aiyer, R. Hu, A. Zwart, M. Johnson, **R. Clarke** (Washington, DC, USA) (30')
- 268. Molecular mechanisms of regulation of *D-glucuronyl C5-epimerase* expression in breast cancer. T.Y. Prudnikova, L.A. Mostovich, A. Kondratov, N. Gubanova, V.I. Rykova, V.I. Kashuba, E.R. Zabarovsky, **E.V. Grigorieva** (Novosibirsk, Russia; Stockholm, Sweden) (15')
- 196. Regulation of estrogen concentrations in the breast. **R.T. Chatterton Jr**, S.A. Khan (Chicago, IL, USA) (15')

BREAST CANCER

Room C, 15:00-16:30
Friday, October 7

Chair Persons: M.A. Nagai, B. Paquette

284. Molecular aspects of the link between obesity, insulin resistance and breast cancer. M. Weichhaus, J. Broom, **G. Bermano** (Aberdeen, UK) (25')
230. Role of the tumor suppressor gene PAR-4 in mammary gland morphogenesis and breast cancer. S.A. De Bessa-Garcia, M.C. Pereira, **M.A. Nagai** (São Paulo, Brazil) (15')
303. Inflammation induced by radiation enhances breast cancer cell invasion. **B. Paquette**, R. Lemay, H. Therriault, M. Lepage (Sherbrooke, Canada) (20')
258. Epithelial-stromal interactions in human breast cancer: Implications for cell adhesion, membrane fluidity and migration. **C. Angelucci**, G. Maulucci, G. Lama, G. Proietti, C. Fabbri, R. Masetti, G. Sica (Rome, Italy) (15')
387. The mitotic kinase Aurora-A promotes breast cancer metastases by inducing a CD24^{low/-} basal-like stem cell phenotype. **A.B. D'Assoro**, T. Liu, Q. Cosima, A. Leontovich, W. Lingle, V. Suman, I. Iankov, A. Di Leonardo, A. Amato, J. Ayers-Inglers, A. Degnim, F. Stivala, M. Libra, J. Ingle, E. Galanis, J.L. Salisbury (Rochester, MN, USA; Catania, Italy) (15')

BREAST CANCER/MOLECULAR MEDICINE

Room C, 17:00-18:30
Friday, October 7

Chair Persons: P. Ozretic, T. Kondo

214. *In silico* methods for assessing potential functional impact of human breast cancer gene BRCA2 sequence variants found in 5' untranslated region. **P. Ozretic**, M.L. Cvok, V. Musani, M. Sabol, D. Car, S. Levanat (Zagreb, Croatia) (30')
209. Glim - A novel glioma stem cell marker and a potential therapeutic target. **T. Kondo** (Kobe, Japan) (15')
170. JAK2V617F mutation and allele burden in patients with essential thrombocythemia. **A. Pich**, L. Riera, E. Beggiato, B. Nicolino, L. Godio, P. Campisi, P.F. Di Celle (Turin, Italy) (15')
242. Gene expression in the adrenal glands of two spontaneously hypertensive rat strains at 3 and 6 weeks of age. **K. Yamanishi**, H. Yamamoto, D. Okuzaki, Y. Watanabe, M. Yoshida, S. Nishiguchi, K. Shimada, H. Okamura, H. Nojima, T. Yasunaga, H. Yamanishi, H. Matsunaga (Hyogo; Osaka, Japan) (15')
148. Chinese medicine in ageing research. Y.B. Li, **P.M. Hoi** (Macau, P.R. China) (15')

COLON CANCER

Room D, 09:00-11:00
Friday, October 7

Chair Persons: F. Boudreau, P. Vodicka, U. Stein

292. Novel biomarkers in patients' blood: Impact on diagnosis and prognosis of colorectal cancer. **U. Stein**, S. Burock, P. Herrmann, I. Wendler, M. Niederstrasser, K.D. Wernecke, P.M. Schlag (Berlin, Germany) (30')
272. DNA repair functional studies and susceptibility to sporadic colorectal cancer. **P. Vodicka**, J. Slyska, L. Vodickova, L. Lipska, V. Polakova, B. Pardini, A. Naccarati (Prague, Czech Republic) (30')
266. Role of the pigment-epithelial-derived-factor in regulating colorectal cancer cell growth and survival. S. St-Jean, C. Jones, M.J. Langlois, N. Rivard, **F. Boudreau** (Sherbrooke, Canada) (20')
273. CpG island methylation in colorectal and head/neck cancers. **L. Vodickova**, N. Stojceva, V. Polakova, B. Pardini, A. Naccarati, J. Slyska, L. Bielik, P. Prochazka, L. Lipska, D. Kovar, P. Soucek, P. Vodicka (Prague, Czech Republic) (20')
329. Efficient protection against malaria is conferred by catalytic antibody stimulation. **J.M. Lozano**, G. Gallego, L. Carreño, M.E. Patarroyo (Bogotá, Colombia) (20')

MOLECULAR ONCOLOGY/CANCER PREVENTION

Room D, 11:30-13:10
Friday, October 7

Chair Persons: I. Eliaz, M. Tanaka

176. Integrative medicine and the role of modified citrus pectin and poly botanicals in cancer prevention and treatment. **I. Eliaz** (Sebastopol, CA; Santa Rosa, CA, USA) (20')
299. Inhibition of cancer cell growth using novel 3D films. **M. Tanaka** (Yonezawa, Japan) (20')
127. HITS (FAM107B): Novel heat-shock induced protein as a marker for cancer progression and diagnosis. **H. Nakajima**, T. Minamoto, Y. Motoo (Ishikawa, Japan) (20')
179. Calcidiol and health, its potential role in anticancer treatments. **Y.-R. Lou**, F. Molnár, M. Peräkylä, S. Qiao, A.V. Kalueff, R. St-Arnaud, C. Carlberg, P. Tuohimaa (Helsinki; Tampere; Kuopio, Finland; Montréal, Canada; Luxembourg) (20')
375. Rapamycin improves tumor oxygenation and vascular renormalization. K. Saito, S. Matsumoto, N. Devasahayam, S. Subramanian, J. Munasinghe, V. Patel, J.S. Gutkind, J.B. Mitchell, **M.K. Cherukuri** (Bethesda, MD, USA) (20')

INFLAMMATION/TRANSFORMATION

Room D, 15:00-16:30

Friday, October 7

Chair Persons: K. Umezawa, N.A.P. Franken

125. Role of peritoneal NF- κ B on inflammation and cancer progression; Lessons from the inhibitor DHMEQ. **K. Umezawa** (Yokohama, Japan) (30')
152. Induction of γ -H2AX foci in lymphocytes, fibroblasts and tumour cells by single and pulsed high dose rate X-irradiation. N. Denswil, S.E. Hovingh, A. Güçlü, L.J.A. Stalpers, H. Vrieling, **N.A.P. Franken** (Amsterdam; Leiden, The Netherlands) (30')
183. Attenuation of liver myofibroblast activation by a small-molecule TGF- β receptor I inhibitor. **C.L. Lim**, R.Y. Koh, H.F. Seow (Kuala Lumpur; Selangor, Malaysia) (15')
218. Noonan syndrome and myeloproliferative evolution: A functional evaluation of circulating hematopoietic progenitors. **F. Timeus**, N. Crescenzo, A. Doria, S. Vallero, L. Foglia, S. Pagliano, C. Rossi, A. Dotta, G. Baldassarre, M. Cirillo, F. Fagioli, L.C. Di Montezemolo, G.B. Ferrero (Turin; Bologna, Italy) (15')

MOLECULAR MEDICINE

Room D, 17:00-18:30

Friday, October 7

Chair Persons: P.A. Ward, H. Yasuda

123. Molecular events in sepsis. **P.A. Ward** (Ann Arbor, MI, USA) (30')
236. Nitric oxide may improve pemetrexed cytotoxicity in lung adenocarcinoma cells. **H. Yasuda**, H. Nagai (Sendai, Japan) (30')
316. Development and molecular characterization of transgenic mice for β -thalassemia. **A. Finotti**, G. Breveglieri, I. Mancini, N. Bianchi, I. Lampronti, F. Salvatori, C. Zuccato, E. Fabbri, E. Brognara, G. Feriotto, M. Borgatti, R. Gambari (Ferrara, Italy) (15')
323. Pathophysiology of calcium processing genes in intestine and kidney. **E.-B. Jeung** (Chungbuk, Republic of Korea) (15')
346. Role of inflammatory cytokines in the development of multiple symptoms in patients with cancer undergoing chemoradiation therapy. **X.S. Wang**, C.S. Cleeland, Q. Shi, Z. Liao, G.M. Mobley, V.E. Johnson (Houston, TX, USA) (15')
238. Relationship between serum IGF-I/IGFBP-3 ratio and hepatic steatosis or insulin resistance in patients with HCV-related chronic liver disease. **T. Himoto**, H. Yoneyama, M. Inukai, H. Masugata, F. Goda, S. Senda, T. Masaki (Kagawa, Japan) (15')

COLON CANCER

Room A, 09:00-11:00
Saturday, October 8

Chair Persons: C. Paraskeva, N. Perreault

134. β -catenin negatively regulates 15-prostaglandin dehydrogenase expression in colorectal cancer cells: Implications for colorectal cancer prevention and stem cell biology. H.J.M. Smartt, A. Greenhough, M. Al-Kharusi, H.R. Roberts, J.M. Mariadson, A.C. Williams, **C. Paraskeva** (Bristol, UK; Melbourne, Australia) (30')
150. Loss of BMP signaling in subepithelial myofibroblasts leads to colonic dysplasia and impacts on ulcerative colitis. J.M. Allaire, S.A. Roy, K.H. Keatsner, F. Boudreau, **N. Perreault** (Sherbrooke, Canada; Philadelphia, PA, USA) (30')
247. Galectins in colorectal cancer progression and metastasis. **L.-G. Yu** (Liverpool, UK) (30')
190. Development of automatic genechip analyzer for detection of the circulating colorectal cancer cells. **S.-R. Lin** (Kaohsiung; Pingtung, Taiwan, R.O.C.) (15')
195. Scrutiny of colorectal carcinoma microenvironment reveals novel, biological prognostic factors: The role of Fc-gamma-RIII and HLA-DR. **G. Sconocchia**, I. Zlobec, S. Eppemberger, A. Lugli, D. Calabrese, G. Iezzi, E. Karamitopoulou, E.S. Patsouris, G. Peros, F. Ferrelli, L. Franceschilli, N. Di Lorenzo, A. Ferlosio, S. Ferrone, G.C. Spagnoli, L. Terracciano (Rome, Italy; Basel, Switzerland; Athens, Greece; Pittsburgh, PA, USA) (15')

EXPERIMENTAL THERAPEUTICS

Room A, 11:30-13:10
Saturday, October 8

Chair Persons: T. Thalhammer, T. Sakai, I. Herr

301. OATP family members in ovarian cancer and their potential role in tumor therapy. M. Svoboda, J. Riha, W. Jäger, D.C. Castilo-Tong, R. Zeillinger, T. van Gorp, I. Vergot, I. Braicu, J. Sehouli, S. Mahner, M. Fogel, **T. Thalhammer** (Vienna, Austria; Berlin; Hamburg, Germany; Leuven, Belgium; Rehovot, Israel) (25')
245. Discovery of clinically useful molecular-targeting agents and diagnostic system based on RB. **T. Sakai** (Kyoto, Japan) (25')
374. Identification and targeting of tumor-initiating cells in pancreatic cancer. **I. Herr**, V. Rausch, G. Kallifatidis, S. Labsch, L. Liu, S. Ottinger, W. Zhou, B. Baumann, J. Mattern, J. Werner, N. Giese, E. Ryschich, P. Schemmer, T. Wirth, G. Moldenhauer, M.W. Büchler, A.V. Salnikov (Heidelberg; Ulm, Germany) (25')
302. Receptor tyrosine kinases signaling in colorectal cancer. **C. Saucier**, J. Bernier, W. Chababi, M.C. Galoul, M. Landry, V. Pomerleau (Sherbrooke, Canada) (25')

METASTASIS

Room A, 16:00-17:30
Saturday, October 8

Chair Persons: W. Brenner, G.K. Menon

124. Calcium sensing in bone metastases of renal cell carcinoma. **W. Brenner**, E. Schneider, K. Junker, F.C. Roos, J.W. Thüroff (Mainz; Jena, Germany) (30')
279. Angiogenesis in haematological malignancies. **G.K. Menon**, K.C. Gatter (Newcastle upon Tyne; Oxford, UK) (30')
248. Isoflurane friend or foe? An *in vitro* study to investigate the effects of isoflurane on metastatic potential of renal and prostate cancer. **L.L. Benzonana**, H. Huang, N.J. Perry, M.P. Vizcaychipi, H. Watts, D. Ma (London, UK; Chengdu, P.R. China) (30')

TUMOR BIOLOGY

Room A, 18:00-19:30
Saturday, October 8

Chair Persons: R. Warrington, V. García

171. Nerve growth factor and the role of natural antibodies in cancer. **R. Warrington** (Winnipeg, Canada) (30')
226. Heat shock proteins and oral lichen planus. **V. García**, A.I. García, R. Küffer, C.P. Martinelly-Kläy, T. Lombardi, A. Bascones (Madrid, Spain; Geneva, Switzerland) (30')
304. Cell and molecular biology of canine angiosarcoma. N. Andersen, Y. Ding, E. Boguslawski, R. Froman, A. Blanski, C. Weisner, J. Smith, K. Furge, K. Dykema, **N. Duesbery** (Grand Rapids, MI, USA) (30')

PROSTATE CANCER

Room B, 09:00-11:00

Saturday, October 8

Chair Persons: P.S. Rennie, G. Perletti, S. Shenoy

207. Identification of novel anti-androgens that target the BF-3 and AF-2 sites of the androgen receptor. N.A. Lack, P. Axerio, E. Le Blanc, E. Guns, A. Cherkasov, **P.S. Rennie** (Vancouver, Canada) (25')
228. Statins for prostate cancer: A friend, a foe or neither. **S. Shenoy**, S.T. Kochuparambil, B. Al-Husein, A. Goc (Augusta, GA, USA) (25')
153. The use of primary circulating prostate cells to detect prostate cancer in men with a serum PSA >4.0 ng/ml: Evidence, utility and cost-benefit. **N.P. Murray**, E. Reyes, N. Orellana, L. Badinez, P. Tapia (Santiago, Chile) (25')
215. Aggressive therapy for chronic prostatitis: Effect on PSA values, inflammatory findings, uropathogen eradication and clinical symptoms. Implications for prostate cancer detection and prevention. **G. Perletti**, E. Montanari, A. Vral, E. Marras, K. Naber, V. Magri (Varese; Milano, Italy; Ghent, Belgium; Munich, Germany) (15')
260. Atomic force microscopy of GnRH membrane receptors in human prostate cancer cells treated with a GnRH agonist. **G. Lama**, C. Angelucci, E. Cupelli, M. Papi, M. De Spirito, G. Sica (Rome, Italy) (15')
269. E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy. **F. Iacopino**, F. Pinto, A. Bertaccini, A. Calarco, G. Proietti, A. Totaro, G. Martorana, P. Bassi, G. Sica (Rome; Bologna, Italy) (15')

MOLECULAR BIOLOGY/PROSTATE CANCER

Room B, 11:30-13:10

Saturday, October 8

Chair Persons: D. Sliva, N. Wernert

276. Molecular mechanisms of the inhibition of prostate cancer by the dietary supplement ProstaCaid. **D. Sliva**, I. Eliaz, J. Jiang (Indianapolis, IN; Sebastopol, CA, USA) (30')
332. Prostate cancer and ETS transcription factors. **N. Wernert**, Z. Shaikhibrahim, G. Kristiansen, S. Perner (Bonn, Germany) (25')
296. Secretory phospholipase A2-IIa, a potential biomarker for prostate cancer, is regulated by the HER/HER2-elicited pathway. L. Oleksowicz, Y. Liu, R.B. Bracken, K. Gaitonde, B. Burke, P. Succop, L. Levin, Z. Dong, **S. Lu** (Cincinnati, OH, USA) (15')
270. Synergistic effect of epigenetic factors and FK506-binding protein 51 on biological behavior of skin melanoma. **M. Mascolo**, M. Siano, G. Ilardi, G. De Rosa, S. Staibano (Naples, Italy) (15')
378. Deregulation of micro-RNAs (miR-21, miR146a and let-7a) induced by DMBA in CBA/CA mice. K. Juhász, K. Gombos, M. Szirmai, P. Révész, I. Magda, K. Gőcze, **I. Ember** (Pécs, Hungary) (15')

EXPERIMENTAL THERAPEUTICS/BRAIN TUMORS

Room B, 16:00-17:30
Saturday, October 8

Chair Persons: G. Sica, R. Veselska, H.M. Said

256. Cancer stem cells from glioblastoma and peritumor tissue. G. Lama, A. Colabianchi, G. Proietti, A. Mangiola, P. De Bonis, E. Binda, G. Maira, A. Vescovi, **G. Sica** (Rome; Milano, Italy) (25')
281. Intracellular distribution of N-terminal isoforms of the p73 protein in medulloblastoma cell lines. **R. Veselska**, K. Zitterbart, M. Nekulova, L. Dobrucka, J. Neradil, P. Chlapek, J. Sterba (Brno, Czech Republic) (25')
282. Potential functional therapeutic alternatives for the treatment of human brain cancer. **H.M. Said**, C. Hagemann, C.T. Supuran, A. Staab, M. Flentje, D. Vordermark (Wuerzburg; Halle, Germany; Florence, Italy; Zurich, Switzerland) (25')
164. The significance of SDHB immunohistochemistry and FISH analysis on pheochromocytomas and extra-adrenal paragangliomas. **N. Kimura**, J. Saito, A. Horii, S. Ito (Hakodate; Yokohama; Sendai, Japan) (25')

BRAIN TUMORS/IMMUNOLOGY

Room B, 18:00-19:30
Saturday, October 8

Chair Persons: M. Reiniš, A. Sedo

255. MHC class I-deficient tumours and their effective chemoimmunotherapy using 5-azacytidine treatment. **M. Reiniš**, J. Šimová, V. Polláková, M. Indrová, R. Mikyšková, I. Štěpánek, J. Bieblova, J. Bubeník (Prague, Czech Republic) (25')
286. Dipeptidyl peptidase-IV (DPP-IV) and fibroblast activation protein- α (FAP) in gliomagenesis. E. Balaziová, P. Busek, **A. Sedo** (Prague, Czech Republic) (25')
243. Identification of novel targets in brain tumor stem cells. **H. Wurdak** (Leeds, UK) (20')
244. Tumor microenvironment in the brain. **M. Lorgier** (Leeds, UK) (20')

COLON CANCER/GYNECOLOGICAL CANCER

Room C, 09:00-11:00

Saturday, October 8

Chair Persons: M. El-Salhy, P. Soucek

122. Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. **M. El-Salhy**, D. Gundersen, H. Østgaard, B. Lomholt-Beck, J.G. Hatlebakk, T. Hausken (Stord; Haugesund; Bergen, Norway) (30')
274. Role of ABC transporters in clinical outcome of cancer. **P. Soucek**, V. Hlavac, I. Hlavata, V. Pecha, M. Trnkova, V. Liska, R. Vaclavikova (Prague, Czech Republic) (30')
366. Role of *p14^{ARF}* alterations in endometrial tumorigenesis. **A. Semczuk**, K. Ciepliński, A. Ignatov, P. Olcha, M. Gogacz, K. Gałczyński, B. Marzec, T. Rechberger (Lublin; Plock, Poland; Magdeburg, Germany) (15')
158. Tumor antagonizing genes and ovarian cancer: The role of the human RNASET2 gene. **F. Acquati**, L. Monti, S. Bertilaccio, M. Lualdi, A. Grimaldi, R. Cinquetti, P. Bonetti, P. Ghia, F. Sanvito, C. Doglioni, C. Riva, C. Capella, D. Noonan, A. Sica, R. Taramelli (Varese; Milano; Rozzano, Italy) (15')
200. Mechanistic involvement of the microRNA miR-145 in the pathogenesis of endometriosis. M. Adammek, B. Greve, N. Kässens, L. Kiesel, **M. Götte** (Münster, Germany) (15')
360. Treatment for advanced colorectal liver metastases in the era of chemotherapy - Role of hepatectomy in treating multiple bilobar colorectal cancer metastases. **K. Nojiri**, K. Tanaka, K. Takeda, M. Sugita, M. Ueda, R. Matsuyama, K. Taniguchi, T. Kumamoto, R. Mori, J. Watanabe, M. Ota, Y. Ichikawa, I. Endo (Yokohama, Japan) (15')

CLINICAL ONCOLOGY/SURGICAL ONCOLOGY

Room C, 11:30-13:10

Saturday, October 8

Chair Persons: G.P. Stathopoulos, G. Tsoulfas

133. A new cytotoxic agent, liposomal cisplatin: Low toxicity, high effectiveness. **G.P. Stathopoulos**, S. Rigatos, J. Stathopoulos, S. Batzios (Athens, Greece) (20')
114. Novel surgical therapies in the treatment of hepatic metastases from colorectal cancer. **G. Tsoulfas** (Thessaloniki, Greece) (20')
115. Current role of surgery in the treatment of hepatocellular carcinoma, ranging from resection to liver transplantation, including new molecular targeted therapies. **G. Tsoulfas** (Thessaloniki, Greece) (15')
251. Prevention of resistance development in renal cell carcinoma by combined inhibition of mammalian target of rapamycin and histone deacetylase. **E. Juengel**, A. Vogt, L. Hudak, J. Makarevic, A. Haferkamp, R. Blaheta (Frankfurt/Main, Germany) (15')
295. Gene expression signature differences in breast cancer molecular classification. **A. Armakolas**, G.P. Stathopoulos, A. Nezos, A. Theos, M. Stathaki, M. Koutsilieris (Athens, Greece) (15')
373. Long term survival in children with acute leukemia and complications requiring mechanical ventilation. **D. Steinbach**, B. Wilhelm, H.-R. Kiermaier, U. Creutzig, M. Schrappe, M. Zimmermann, K.-M. Debatin, B. Gruhn, A. von Stackelberg, H. Jürgens, B. Strahm, D. Reinhardt, A. Möricke (Ulm; Münster; Kiel; Hannover; Jena; Berlin; Freiburg, Germany) (15')

INFECTIOUS DISEASES

Room C, 16:00-17:30
Saturday, October 8

Chair Persons: M.K. Leinonen, M. Libra, G. Sourvinos

187. Cervical cancer and precancerous lesions associated with high-risk HPV types in Finnish screening population. **M.K. Leinonen**, A. Anttila, P. Nieminen (Helsinki; Espoo, Finland) (25')
340. B-cell neoplasia in the context of HCV infection: A distinct entity? **M. Libra**, S. Travali, F. Nicoletti, M.C. Mazzarino, F. Stivala (Catania, Italy) (20')
264. Role of viral infection in melanoma development and progression. **S. Staibano**, G. Ilardi, M. Siano, M. Mascolo, G. De Rosa (Naples, Italy) (15')
347. Cellular microRNA signature during human cytomegalovirus infection. **N. Goulidaki**, D.A. Spandidos, D. Iliopoulos, G. Sourvinos (Heraklion, Greece; Boston MA, USA) (15')
362. The role of extracellular-signal-regulated kinase (ERK) activation during herpes simplex virus type-1 (HSV-1) lytic infection. **H. Filippakis**, D. Thiriou, D.A. Spandidos, G. Sourvinos (Heraklion, Greece) (15')

MOLECULAR MEDICINE/EXPERIMENTAL THERAPEUTICS

Room C, 18:00-19:30
Saturday, October 8

Chair Persons: G.Z. Chen, O.T. Murray, L.M. Junie

285. Detection and treatment of metastatic cancers using nanotechnology. **G.Z. Chen**, D. Huang, X. Wang, J. Xu, J. Li, S. Muller, M. Thighiouart, S. Nie, D.M. Shin (Atlanta, GA, USA) (30')
306. Phosphosulindac inhibits pancreatic cancer growth. **O.T. Murray**, K. Vrankova, F. Johnson, B. Rigas (Stony Brook, NY, USA) (30')
322. Molecular basis of the antibiotic resistance and its importance in the hospital acquired infections. **L.M. Junie** (Cluj Napoca, Romania) (30')

MOLECULAR MEDICINE/MOLECULAR ONCOLOGY

Room D, 09:00-11:00
Saturday, October 8

Chair Persons: N. Telang, S.L. Habib

- 159. Isogenic human breast epithelial cell lines: Model for cancer initiating stem cells. **N. Telang**, M. Katdare (Montvale, NJ; Hampton, VA, USA) (25')
- 305. Diabetes and the risk of renal cell carcinoma. **S.L. Habib** (San Antonio, TX, USA) (25')
- 219. A new look on cancer-selective therapy: NSC 631570. **L.M. Skivka** (Kyiv, Ukraine) (25')
- 333. Transgenic pigs for medicine and agriculture. **S.-H. Hyun**, E.-B. Jeung, W.-S. Hwang (Cheongju; Seoul, Republic of Korea) (15')
- 157. RNA expression profiling of archival tongue carcinoma samples. **M. Rentoft**, E. Johnsson, G. Laurell, P.J. Coates, K. Nylander (Umeå, Sweden; Dundee, UK) (15')
- 249. Complex chromosomal aberrations in Syrian CML patients. **W. Al Achkar**, W. Abdulsamad, F. Mouassass (Damascus, Syria) (15')

ALTERNATIVE MEDICINE AND CANCER PREVENTION

Room D, 11:30-13:10
Saturday, October 8

Chair Persons: E. Agostinelli, J. Michalek, E.R. Zabarovsky

- 367. Chloroquine (CQ) and the aldehyde piperidine oximether (EHW437) potentiate the cytotoxicity of spermine metabolite on human cancer cells. **E. Agostinelli**, G. Tempera, N. Viceconte, S. Saccoccio, M. Condello, G. Bozzuto, A. Calcabrini, G. Arancia, A. Molinari (Rome, Italy) (25')
- 280. Identification of new methylation-regulated genes as molecular targets for pharmaceutical intervention and diagnosis based on NotI microarrays. V.I. Kashuba, E.V. Grigorieva, K. Haraldson, V.N. Senchenko, A.A. Dmitriev, T. Pavlova, E.A. Braga, S.P. Yenamandra, N. Soultzis, D.A. Spandidos, G. Klein, M.I. Lerman, **E.R. Zabarovsky** (Stockholm, Sweden; Heraklion, Greece) (25')
- 145. Comparison of different dendritic cell preparation strategies for potent anti-cancer immunotherapy. **J. Michalek**, R. Hezova, P. Knottigova-Turankova, J. Turanek (Brno, Czech Republic) (25')
- 146. Expression of TLE1 is a new biomarker for synovial sarcomas and correlates with t(X;18): Analysis of 319 cases. **T. Knösel**, S. Heretsch, A. Altendorf-Hofmann, D. Katenkamp, A. Berndt, I. Petersen (Jena, Germany) (25')

POSTERS

110. Continuous approach for knockdown of GRP78 fails to downregulate GRP78 protein expression but increases sensitivity to cisplatin in HeLa cells. **T. Suzuki**, J. Lu, G. Hu, K. Kita, N. Suzuki (Chiba; Ichikawa, Japan)
116. Inhibition of the DNA binding activities of Erg transcription factor using heterocyclic diamidines as sequence-specific DNA ligands. R. Nhili, P. Peixoto, S. Depauw, M. Duterque-Coquillaud, D.W. Boykin, W.D. Wilson, **M.-H. David-Cordonnier** (Lille, France; Atlanta, GA, USA)
117. DNA binding properties of new diamidino-substituted phenyl-benzothiazolyl/dibenzothiazolyl-furans/thiophenes: Sequence-selective binding and nucleus sub-localisation. R. Nhili, P. Peixoto, S. Depauw, M.-P. Hildebrand, S. Kraljevic-Pavelic, G. Karminski-Zamola, **M.-H. David-Cordonnier** (Lille, France; Zagreb; Rijeka, Croatia)
118. New benzo[c]phenanthrolines derivatives of nitidine and fagaronine: Correlation between cytotoxicity and sequence-selective DNA binding activities. G. Lenglet, R. Nhili, S. Depauw, C. Genès, F.-H. Porée, S. Michel, F. Tillequin, **M.-H. David-Cordonnier** (Lille; Paris, France)
119. Sequence selective binding of the DNA helix by heterocyclic diamidines: From 5'-AATT to a 5'-TTAA selectivity. R. Nhili, S. Depauw, M. Munde, A. Kumar, D.W. Boykin, W.D. Wilson, **M.-H. David-Cordonnier** (Lille, France; Atlanta, GA, USA)
120. Targeting of the DNA binding properties of Pit-1 and Brn3a transcription factors using new DNA ligands deriving from the diamidine-phenyl-furan-benzimidazole. P. Paul, S. Depauw, N. Raja, D.W. Boykin, W.D. Wilson, **M.-H. David-Cordonnier** (Lille, France; Atlanta, GA, USA)
135. Changes in gene expression in neuroblastoma and medulloblastoma cell lines during induced differentiation by combined treatment with all-*trans* retinoic acid and LOX/COX inhibitors. **P. Chlapek**, M. Redova, J. Neradil, K. Zitterbart, M. Hermanova, J. Sterba, R. Veselska (Brno, Czech Republic)
140. The stem cell marker nestin regulates growth, invasion and stemness of malignant melanomas. **M. Akiyama**, K. Kawahara, Y. Matsuda, R. Takayama, T. Yamamoto, T. Ishiwata, S. Kawana, Z. Naito (Tokyo, Japan)
141. Expression and roles of nestin in human uterine cervical intraepithelial neoplasia and cervical cancer. **A. Sato**, T. Ishiwata, K. Kawahara, T. Yamamoto, Y. Matsuda, H. Asakura, T. Takeshita, Z. Naito (Tokyo, Japan)
142. Immunohistochemical analysis of cancer stem cell markers in human pancreatic cancer tissues. **T. Yamamoto**, Y. Matsuda, Y. Kawamoto, K. Kawahara, Z. Naito, T. Ishiwata (Tokyo, Japan)
181. Live xenogenic mouse tumor cells as prophylactic vaccines for human melanoma and breast cancer. **V. Sologub**, V. Keshelava, I. Koromyslova, S. Severin (Moscow, Russia)
182. The role of VEGF in lymph node metastasis in head and neck squamous cell carcinoma. **E. Koudounarakis**, A. Karatzanis, G. Velegarakis (Heraklion, Greece)
184. Effect of *Strobilanthes crispus* extracts on various cancer cell lines. **R.Y. Koh**, H.M. Chong, M.K.M. Yip, W.F. Low, S.H.S. Chong, A.P.K. Ling, S.M. Chye (Kuala Lumpur, Malaysia)
185. Involvement of PI3K/Akt-modulated expression of Bcl-2 and Bax in para-phenylenediamine induce apoptosis in NRK52E cells. **S.M. Chye**, W.C. Ng, W.K. Yip, R.Y. Koh, H.F. Seow (Kuala Lumpur, Malaysia)
186. Screening of anti-dengue activity in methanolic extracts of six medicinal plants. **A.P.K. Ling**, L.I.C. Tang, S.M. Chye, R.Y. Koh (Kuala Lumpur, Malaysia)
191. Genotype profile of ERCC1, XPD and EGFR genes in poor prognostic Taiwanese CRC patients. **M.-Y. Huang**, S.-R. Lin (Kaohsiung, Taiwan, R.O.C.)

193. AGR2 protein expression contributes to tumour behaviour *via* p53 inhibitory effect. **R. Hrstka**, P. Hublarová, V. Brychtová, M.M. Maslon, E. Murray, T.R. Hupp, B. Vojtěšek (Brno, Czech Republic; Edinburgh, UK)
197. GST Pi expression predicts benefit from 5FU-based chemotherapy after resection of stage C colon cancer. **L. Jankova**, O.F. Dent, C. Chan, K. Tan, C. Fung, M. Molloy, P.H. Chapuis, L. Bokey, G. Robertson, S.J. Clarke (Sydney, Australia)
198. Glutathione-S-transferase and microsomal epoxide hydrolase gene polymorphisms and risk of prostate cancer in the Slovak population. **M. Kmet'ová Sivoňová**, D. Dobrota, T. Matáková, R. Dušenka, J. Kliment (Martin, Slovakia)
203. The importance of determination mRNA ABC-transporters and apoptotic proteins in patients with acute leukaemia. **J. Hatok**, J. Jurecekova, M. Kmetova Sivonova, A. Stefanikova, D. Dobrota, P. Racay (Martin, Slovakia)
223. Detection of the circulating tumor cells in gynecologic cancers. **T. Sasaki**, H. Nishi, Y. Nagamitsu, C. Higuma, Y. Takaki, F. Terauchi, K. Isaka (Tokyo, Japan)
227. Analysis of HGG-02 cell line with loss of *EGFR* gene copy derived from childhood glioblastoma multiforme. **J. Skoda**, J. Neradil, T. Loja, K. Zitterbart, Z. Pavelka, E. Brichtova, J. Smardova, I. Valaskova, M. Hermanova, J. Sterba, R. Veselska (Brno, Czech Republic)
231. PAR-4 and PHLDA1 expression regulation by estrogen and epidermal growth factor in MCF-7 breast cancer cells. S.A. De Bessa-Garcia, M.C. Pereira, **M.A. Nagai** (São Paulo, Brazil)
232. Tanshinone IIA could inhibit human hepatocellular carcinoma J5 cells tumor growth in a murine xerograft model through increasing ATF4 and JNK expression. **C.-C. Su**, S.-Y. Chien, S.-J. Kuo, Y.-L. Chen, D.-R. Chen (Changhua; Taichung, Taiwan, R.O.C.)
233. Lynch syndrome in the Czech Republic: Mutation analysis of the *MLH1* and *MSH2* genes in patients selected according to clinical criteria. **A. Krepelova**, K. Pavlikova, P. Vasovcak, A. Puchmajerova, P. Plevova, L. Foretova (Prague; Ostrava; Brno, Czech Republic)
235. The clinicopathological study of P-glycoprotein and combination chemotherapy with cyclophosphamide, adriamycin and cisplatin in ovarian cancer. **K. Yamamoto** (Osaka, Japan)
250. Establishment of a cell line from a Japanese patient with sarcomatoid malignant pleural mesothelioma. **H. Yamamoto**, Y. Mimura, K. Aoe, H. Tao, E. Matsuda, F. Sano, K. Okabe, K. Sugi, T. Matsumoto, H. Ueoka (Yamaguchi, Japan)
252. Breastfeeding and transmission of maternal human papillomavirus to infants. **I.N. Mammas**, G. Sourvinos, E. Vakonaki, C. Koutsaftiki, A. Zaravinos, N. Myriokefalitakis, M. Theodoridou, D.A. Spandidos (Heraklion; Palaia Penteli; Athens, Greece)
253. Tigecycline elicits cytotoxicity on transitional cell carcinoma cells *in vitro*. **P.C. Lai**, Y.T. Huang, C.C. Wu, C.C. Cheng, Y.F. Lan, T.H. Chiu (Hualien, Taiwan, R.O.C.)
254. Preclinical evaluation of thalidomide for bladder cancer therapy. **Y.T. Huang**, P.C. Lai, C.C. Wu, C.C. Cheng, T.H. Chiu (Hualien, Taiwan, R.O.C.)
259. The effect of nitroxide Pirolin and its combination with doxorubicin and docetaxel on oxidative stress in heart of rats bearing mammary tumors. **K. Gwozdziński**, S. Tabaczar, J. Czepas, J. Piasecka-Zelga, A. Polit, A. Koceva-Chyla (Lodz, Poland)
262. High-grade prostate cancer vs. prostate cancer metastases: Difference in gene expression in cell lines. **M. Masarik**, J. Gumulec, M. Hlavna, M. Sztalmachova, P. Babula, V. Adam, S. Krizkova, R. Hrabec, A. Rovny, R. Kizek (Brno, Czech Republic)
263. Analysis of tumor markers in prostate carcinoma at RNA and protein level. **M. Masarik**, J. Gumulec, M. Hlavna, M. Sztalmachova, P. Babula, V. Adam, S. Krizkova, R. Hrabec, A. Rovny, R. Kizek (Brno, Czech Republic)

271. Genetic diagnosis for chemosensitivity with paclitaxel-sensitive genes in epithelial ovarian cancer. **H. Nishi**, T. Sasaki, Y. Takaesu, Y. Nagamitsu, C. Higuma, F. Terauchi, M. Kuroda, K. Isaka (Tokyo, Japan)
289. Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. M.A.B. Lozovoy, A.N.C. Simão, T.N.C. Simão, S.R. De Oliveira, A.P. Kallaur, **H.K. Morimoto**, E. Da Silva, D. De L. Petenuci, E.M.V. Reiche, I. Dichi (Londrina, Brazil)
290. Oxidative stress is associated with liver damage, inflammatory status, and corticosteroid therapy in patients with systemic lupus erythematosus. M.A.B. Lozovoy, A.N.C. Simão, E.R.D. De Almeida, E. Da Silva, D. De Lima Petenuci, T. Flauzino, S.R. De Oliveira, E.M.V. Reiche, **H.K. Morimoto**, I. Dichi (Londrina, Brazil)
291. Metabolic syndrome and insulin resistance are increased in patients with human immunodeficiency virus type 1 (HIV-1) infection. **H.K. Morimoto**, E.R.D. De Almeida, S.R. Oliveira, A.N.C. Simão, M.A.B. Lozovoy, L.T. Ueda, J.A. De Oliveira, D.S. Barbosa, E.M.V. Reiche (Londrina, Brazil)
294. Oxidative stress evaluation in overweight subjects with or without metabolic syndrome. D. Venturini, A.N.C. Simão, M.A.B. Lozovoy, T.N.C. Simão, **H.K. Morimoto**, I. Dichi (Londrina, Brazil)
297. Transcript levels of MMPs and ADAMTS-4 in lumbar intervertebral disc herniation. **A. Tsarouhas**, G. Soufla, P. Katonis, D. Pasku, A. Vakis, D.A. Spandidos (Heraklion, Greece)
298. Transcript levels of growth factors in lumbar intervertebral disc herniation. **A. Tsarouhas**, G. Soufla, P. Katonis, D. Pasku, A. Vakis, D.A. Spandidos (Heraklion, Greece)
309. Adenosine stimulated the growth of dermal papilla and elongated the anagen phase by increasing cysteine in organ culture of mouse vibrissae hair follicles through fibroblast growth factor 2 and 7. K.-A. Hwang, **K.-C. Choi** (Chungbuk, Republic of Korea)
310. Growth of breast cancer cells can be inhibited by human amniotic fluid-derived stem cells expressing cytosine deaminase (CD) and thymidine kinase (HSV-TK) in *in vitro* and *in vivo* xenograft models. N.-H. Kang, **K.-C. Choi** (Chungbuk, Republic of Korea)
311. Effect of human amniotic membrane-derived epithelial stem cells on breast cancer cell growth and their therapeutic potential in cellular and *in vivo* xenograft models. N.-H. Kang, M.-A. Park, K.-A. Hwang, H.-R. Lee, E.-B. Jeung, **K.-C. Choi** (Chungbuk, Republic of Korea)
312. Insertion of fusion genes including cytosine deaminase and interferon-beta into stem cells resulted in the inhibition of breast cancer cell growth and migrated to this type of cancer via their tumor tropism. B.-R. Yi, E.-B. Jeung, **K.-C. Choi** (Chungbuk, Republic of Korea)
313. Synergic effects of engineered stem cells expressing cytosine deaminase and interferon-beta on the growth of human gastric cancer via their migratory capability. B.-R. Yi, **K.C. Choi** (Chungbuk, Republic of Korea)
317. Encapsulation of mithramycin into polymeric micelles by microfluidics: Regulation of the expression of the human γ -globin genes. L. Capretto, S. Mazzitelli, C. Zuccato, E. Brognara, I. Lampronti, **R. Gambari**, C. Nastruzzi (Southampton, UK; Ferrara, Italy)
318. Corilagin is a potent inhibitor of NF-kappaB activity and expression of TNF-alpha induced IL-8 gene in cystic fibrosis IB3-1 cells. I. Lampronti, **R. Gambari**, M. Borgatti, E. Fabbri, E. Brognara, N. Bianchi, L. Piccagli, M.C.-W. Yuen, C.-W. Kan, D.K.-P. Hau, W.-F. Fong, W.-Y. Wong, K.-H. Lam, R.S.-M. Wong, C.-H. Chui (Ferrara, Italy; Hong Kong, P.R. China)
319. Detection of genomic disorders in unamplified human genomic DNA using an ultrasensitive surface plasmon resonance imaging method. R. D'Agata, L.M. Zanolli, G. Breveglieri, M. Borgatti, A. Finotti, G. Spoto, **R. Gambari** (Catania; Ferrara, Italy)

320. Mithramycin-mediated regulation of raptor gene transcription during erythroid differentiation of K562 cells. N. Bianchi, **A. Finotti**, C. Zuccato, E. Fabbri, M. Borgatti, R. Gambari (Ferrara, Italy)
321. Inhibition of micro RNA 221 biological activity with an anti-miR-221 peptide nucleic acid. E. Brognara, E. Fabbri, N. Bianchi, **A. Finotti**, G. Breveglieri, M. Borgatti, A. Manicardi, R. Corradini, R. Marchelli, R. Gambari (Ferrara; Parma, Italy)
324. Calcium transport genes including TRPV6, PMCA1, NCXK3, and calbindin-28k were differentially expressed in the placentas of preeclamptic women during pregnancy. H. Yang, S.-H. Hyun, K.-C. Choi, **E.-B. Jeung** (Chungbuk, Republic of Korea)
325. Calcium transport genes including NCX, TRPV6 and calbindins were distinctly controlled by putative steroids in the diverse placental tissues of calbindin-D9k and -28k knockout mice. T.-H. Koo, **E.-B. Jeung** (Chungbuk, Republic of Korea)
326. Endoplasmic reticulum stress-related genes appear to be regulated by sex-steroid hormones, estrogen and progesterone, in the endometrial tissues of calbindin-D9k and -28k knockout mice. E.-M. Jung, K.-C. Choi, **E.-B. Jeung** (Chungbuk, Republic of Korea)
327. Calcium transport-related genes including TRPV6, PMCA1, NCKX3 and calbindin-28k appeared to be distinctly regulated by hypoxia in human placental BeWo cells. H. Yang, **E.-B. Jeung** (Chungbuk, Republic of Korea)
328. Transcriptional activation of the Akt/PKB pathway in lumbar intervertebral disc herniation. D. Pasku, **G. Soufla**, P. Katonis, A. Tsarouhas, A. Vakis, D.A. Spandidos (Heraklion, Greece)
334. Bioactivation of diosmetin to the flavone luteolin, via CYP1A2-catalyzed metabolism in liver hepatoma HepG2 cells. **V.P. Androutsopoulos**, D.A. Spandidos (Heraklion, Greece)
335. Isoproterenol treatment modulates matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor-2 (TIMP-2) expression in rat parotid gland. F. D'Amico, **E. Skarmoutsou**, K. Mangano, F. Stivala, G. Quaderno, G. Malaponte, M.C. Mazzarino (Catania, Italy)
336. Association of single nucleotide polymorphisms of MMP-9 -1562 and TIMP-1 +372 with systemic sclerosis. **E. Skarmoutsou**, F. D'Amico, M. Marchini, F. Stivala, F. Maira, G. Malaponte, R. Scorza, M.C. Mazzarino (Catania; Milano, Italy)
337. Transcription factor binding motifs, chromosome mapping and gene ontology analysis in cross-platform microarray data from bladder cancer. **A. Zaravinos**, G.I. Lambrou, D. Volanis, I. Boulalas, D. Delakas, D.A. Spandidos (Heraklion; Goudi; Voula, Greece)
338. Cross-platform comparisons of microarray data: Elucidation of common differentially expressed genes in bladder cancer. **A. Zaravinos**, G.I. Lambrou, I. Boulalas, D. Volanis, D. Delakas, D.A. Spandidos (Heraklion; Goudi; Voula, Greece)
339. microRNA implication in urinary bladder cancer. **A. Zaravinos**, J. Radojicic, G.I. Lambrou, D. Volanis, D. Delakas, E.N. Stathopoulos, D.A. Spandidos (Heraklion; Goudi; Voula, Greece)
341. Osteopontin/matrix metalloproteinases pathway activation in head and neck cancer. **B. Bruni**, M. Libra, M.S. Candido, N. Vella, G. Malaponte, S. Travali, M.C. Mazzarino, F. Stivala (Catania, Italy)
342. Analysis of BRAF and PI3K mutations in melanoma from UV-exposed workers. **A. Marconi**, V. Rapisarda, M. Libra, L. Proietti, G. Malaponte, C. Fenga (Catania; Messina, Italy)
343. Transcription analysis of neutrofil associated lipocalin (NGAL) in hepatocellular carcinoma. **S. Candido**, F.M. Pezzino, N. Vella, M. Libra, M. Cervello, G. Montalto, S. Travali, J.A. McCubrey, F. Stivala (Catania; Palermo, Italy; Greenville, NC, USA)
344. Role of the transcription factor Yin Yang 1 in non-Hodgkin's lymphoma. **S. Hafsi**, F. Pezzino, G. Ligresti, Z. Soua, S. Travali, M. Libra (Catania, Italy; Sousse, Tunisia)

345. Detection of B-Raf mutations in ovarian cancer is associated with chemoresistance. **A.E. Russo**, I. Pellizzari, S. Candido, F. Pezzino, R. Sorio, G. Baldassarre, S. Canevari, J.A. McCubrey, M. Libra, A. Scalisi, F. Stivala (Catania; Aviano; Milano, Italy; Greenville, NC, USA)
348. OncomiR and tumor-suppressor miR expression in triple-negative primary breast cancer. J. Radojicic, **A. Zaravinos**, T. Vrekoussis, M. Kafousi, D.A. Spandidos, E.N. Stathopoulos (Heraklion, Greece)
350. Cancer diseases and vitamin D. **R. Fuchsova**, O. Topolcan, P. Pazdiora, S. Svobodova, J. Vrzalova, G. Krakorova, M. Spisakova, V. Treska, I. Treskova, M. Pesek, J. Finek (Pilsen, Czech Republic)
351. IGF 1 and colorectal, lung and prostate cancer. **R. Fuchsova**, R. Kučera, S. Svobodova, A. Narsanska, J. Vrzalova, I. Treskova, M. Spisakova, V. Treska, L. Pecen, O. Topolcan (Klatovy; Pilsen, Czech Republic)
352. Measurement of angiogenesis promoters and cytokines in intraocular fluid of patients with proliferative diabetic retinopathy. **J. Vrzalova**, M. Kozova, S. Rusnak, R. Ricarova, O. Topolcan (Pilsen, Czech Republic)
353. Molecular analysis of human melanoma by a proteomic approach. **E. Caputo**, F.M. Pezzino, L. Maiorana, V. Vasta, G. Elia, M. Libra, S. Travalì (Naples; Catania, Italy; Galway; Dublin, Ireland)
361. Antiproliferative and CYP1-inductive effects of the flavones eupatorin-5-methyl ether and luteolin in MCF-7 breast adenocarcinoma cells. **V.P. Androutsopoulos**, D.A. Spandidos (Heraklion, Greece)
363. Proteasome inhibition and not NF- κ B inhibition induces apoptosis to resistant cells in glucocorticoid-induced apoptosis. G.I. Lambrou, **A. Zaravinos**, M. Adamaki, D.A. Spandidos, S. Vlahopoulos (Athens; Heraklion, Greece)
368. MiR-195, miR-196b, miR-181c, miR-21 expression levels and MGMT methylation status are associated with clinical outcome in glioblastoma patients. R. Lakomy, J. Sana, S. Hankeova, P. Fadrus, L. Kren, M. Svoboda, **O. Slaby** (Brno, Czech Republic)
369. Synthesis and characterisation of chitosan-based oil-in-water microcapsules for skin caring fibrous materials. M.C.W. Yuen, C.W. Kan, K.L. Cheuk, J.C.O. Tang, W.A. Daoud, **C.H. Chui**, C.S. Yan (Kowloon, Hong Kong; Victoria, Australia)
372. The impact of single nucleotide polymorphisms of the KCNE1 gene on susceptibility to atrial fibrillation post cardiac surgery: Rational and study design. **K. Voudris**, A. Zaravinos, S. Apostolakis, V. Michopoulou, P. Karyofilis, D.A. Spandidos (Heraklion; Athens, Greece)
376. Detection of a CCR5 gene polymorphism in patients with Lichen Planus. **M. Ntaoukakis**, E. Vakonaki, E. Sarchianaki, A. Sklavounou, K. Krasagakis, D.A. Spandidos (Heraklion; Athens, Greece)
377. Vasorelaxation of two isoflavonoids, calycosin and formononetin, in rat isolated mesenteric artery and their potential relationship to cannabinoid CB₁ receptor. **H.-L. Tseng**, P.M. Hoi (Macau, P.R. China)
380. Select heterozygous Keap1 mutations have a dominant-negative effect on wild-type Keap1 *in vivo*. **T. Suzuki**, J. Maher, M. Yamamoto (Sendai, Japan)
383. Overexpression and ratio disruption of Δ Np63 and TAp63 isoforms in endometrial adenocarcinoma. **E. Vakonaki**, N. Soultzis, S. Sifakis, D. Papadogianni, D. Koutroulakis, D.A. Spandidos (Heraklion, Greece)
384. Use of the GenoType Mycobacterium assay for rapid detection of nontuberculous mycobacteria in routine clinical laboratory. **V. Bantouna**, F. Kontos, Z. Gitti, D.A. Spandidos (Athens; Heraklion, Greece)
385. Evaluation of the new GenoType MTBDRs[®] assay for rapid detection of resistance in *Mycobacterium tuberculosis* isolates at a low-incidence community. **V. Bantouna**, F. Kontos, Z. Gitti, D.A. Spandidos (Athens; Heraklion, Greece)
386. Isolation of *Mycobacterium massiliense* from the pleural fluid of an immunocompromised patient: A case report. **V. Bantouna**, F. Kontos, M. Zande, Z. Gitti, D.A. Spandidos (Heraklion; Athens, Greece)